Merck, Inc.

🇵🇭Philippines

Country: 🇵🇭Philippines

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: MK633

First Posted Date: 2007-01-05

Last Posted Date: 2015-09-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 266

Registration Number: NCT00418613

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Phase 1

Completed

Conditions: Hemodialysis
Renal Insufficiency

First Posted Date: 2007-01-04

Last Posted Date: 2015-08-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT00418366

A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Phase 3

Completed

Conditions: Hepatitis B

Interventions: Biological: Modified Process Hepatitis B Vaccine (Experimental)
Biological: Hepatitis B Vaccine (Recombinant)

First Posted Date: 2006-12-21

Last Posted Date: 2017-05-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1718

Registration Number: NCT00414050

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Phase 2

Completed

Conditions: HPV Infections

Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)

First Posted Date: 2006-12-15

Last Posted Date: 2017-04-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 107

Registration Number: NCT00411749

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Phase 3

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Interventions: Drug: sitagliptin phosphate

First Posted Date: 2006-12-14

Last Posted Date: 2016-02-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 319

Registration Number: NCT00411554

A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

First Posted Date: 2006-12-05

Last Posted Date: 2015-10-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 571

Registration Number: NCT00407927

Locations: 🇺🇸
Allergy Asthma Research Institute, Waco, Texas, United States
🇺🇸
Biogenics Research Institute, San Antonio, Texas, United States
🇺🇸
Allergy & Asthma Associates, Austin, Texas, United States

and more 4 locations

Dyskinesia in Parkinson's Disease (Study P04501)

Phase 2

Completed

Conditions: Parkinson Disease
Movement Disorders
Central Nervous System Diseases
Neurodegenerative Diseases
Brain Diseases

Interventions: Drug: Preladenant
Drug: Placebo
Drug: L-dopa
Drug: Other Parkinson's Disease treatments

First Posted Date: 2006-12-04

Last Posted Date: 2018-11-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 253

Registration Number: NCT00406029

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: MK0457

First Posted Date: 2006-11-29

Last Posted Date: 2015-01-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 52

Registration Number: NCT00405054

The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: MK0633

First Posted Date: 2006-11-28

Last Posted Date: 2015-10-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 688

Registration Number: NCT00404313

Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Disease

First Posted Date: 2006-11-27

Last Posted Date: 2016-11-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 500

Registration Number: NCT00403715

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy